Myeloid cell tropism enables MHC-E–restricted CD8 + T cell priming and vaccine efficacy by the RhCMV/SIV vaccine

Author:

Hansen Scott G.1ORCID,Hancock Meaghan H.1ORCID,Malouli Daniel1ORCID,Marshall Emily E.1ORCID,Hughes Colette M.1,Randall Kurt T.1,Morrow David1ORCID,Ford Julia C.1ORCID,Gilbride Roxanne M.1,Selseth Andrea N.1ORCID,Trethewy Renee Espinosa1,Bishop Lindsey M.1ORCID,Oswald Kelli2ORCID,Shoemaker Rebecca2,Berkemeier Brian2ORCID,Bosche William J.2ORCID,Hull Michael2,Silipino Lorna2ORCID,Nekorchuk Michael1,Busman-Sahay Kathleen1ORCID,Estes Jacob D.1ORCID,Axthelm Michael K.1ORCID,Smedley Jeremy1ORCID,Shao Danica3,Edlefsen Paul T.3ORCID,Lifson Jeffrey D.2ORCID,Früh Klaus1ORCID,Nelson Jay A.1,Picker Louis J.1ORCID

Affiliation:

1. Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.

2. AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.

3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Abstract

The strain 68-1 rhesus cytomegalovirus (RhCMV)–based vaccine for simian immunodeficiency virus (SIV) can stringently protect rhesus macaques (RMs) from SIV challenge by arresting viral replication early in primary infection. This vaccine elicits unconventional SIV-specific CD8 + T cells that recognize epitopes presented by major histocompatibility complex (MHC)–II and MHC-E instead of MHC-Ia. Although RhCMV/SIV vaccines based on strains that only elicit MHC-II– and/or MHC-Ia–restricted CD8 + T cells do not protect against SIV, it remains unclear whether MHC-E–restricted T cells are directly responsible for protection and whether these responses can be separated from the MHC-II–restricted component. Using host microRNA (miR)–mediated vector tropism restriction, we show that the priming of MHC-II and MHC-E epitope–targeted responses depended on vector infection of different nonoverlapping cell types in RMs. Selective inhibition of RhCMV infection in myeloid cells with miR-142–mediated tropism restriction eliminated MHC-E epitope–targeted CD8 + T cell priming, yielding an exclusively MHC-II epitope–targeted response. Inhibition with the endothelial cell–selective miR-126 eliminated MHC-II epitope–targeted CD8 + T cell priming, yielding an exclusively MHC-E epitope–targeted response. Dual miR-142 + miR-126–mediated tropism restriction reverted CD8 + T cell responses back to conventional MHC-Ia epitope targeting. Although the magnitude and differentiation state of these CD8 + T cell responses were generally similar, only the vectors programmed to elicit MHC-E–restricted CD8 + T cell responses provided protection against SIV challenge, directly demonstrating the essential role of these responses in RhCMV/SIV vaccine efficacy.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3